The triple combination of  STB-C017, aPD-1 and aCTLA-4 prolongs overall survival
Caption The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival
Source Syntekabio, Inc.
Download
Related Press Releases Links Syntekabio发表免疫肿瘤药剂STB-C017的非临床数据
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
Syntekabioが2020年AACR総会で免疫腫瘍薬STB-C017の非臨床データを発表